A new study from the PARADIGM-HF and PARAGON-HF clinical trials found that sacubitril/valsartan significantly reduced the ...

The findings presented at ESC showed that the use of sacubitril/valsartan (Sac/Val) on top of existing recommended HF therapies prompted a greater N-terminal pro-brain natriuretic peptide ...

Mineralys has been on the radar for some biotech investors. Read more about MLYS' hypertension treatment, upcoming trial ...

Medicare Part D provides coverage for Entresto. Learn more about Medicare drug coverage and the costs of Entresto.

Even trace amounts of impurities in medication can spell trouble. Yet, recent research shows that nearly one-third of ...

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that ...

Biocon Chairperson Kiran Mazumdar-Shaw on Thursday called for more investment in research and development to drive innovation ...

Pay a tax of up to 1,900% (not 95%) on the total sales revenue of the medicine selected for price setting. News coverage ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure ...

Eicher Motors, SML Isuzu, MOIL, Hindustan Petroleum Corporation, NHPC, NBCC India, Wipro, Biocon, HDFC Asset Management ...

Q4 2024 Earnings Call Transcript August 28, 2024 Operator: Hello and welcome to the Mesoblast Financial Results for the Full ...

GIFT Nifty traded up by 41 points or 0.16% at 25,433 indicating a positive opening for domestic indices NSE Nifty 50 and BSE ...